Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Adamson

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
JAMA Pediatrics|August 14, 2013
Unintended consequences of regulatory initiatives in childhood cancer drug developmentPeter C Adamson
The Oncologist|January 17, 2020
Early Phase Pediatric Cancer Trials: Progress Highlights ChallengesPeter C Adamson
JAMA Pediatrics|June 3, 2014
Too few medicines for children with cancer--replyPeter C Adamson
Annals of Internal Medicine|July 6, 2022
My Patient PortalPeter C Adamson
Pediatric Radiology|December 17, 2008
Imaging in early phase childhood cancer trialsPeter C Adamson
Pediatric Blood & Cancer|April 5, 2021
Foreword to special issue on radiation oncologyPeter C Adamson, Giorgio Perilongo
Cancer Investigation|October 24, 2007
Tyrosine kinase inhibitors in pediatric malignanciesJeffrey M Skolnik, Peter C Adamson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
All dex'ed out with nowhere to go?Peter C Adamson, Jeffrey S Barrett
Cancer Chemotherapy and Pharmacology|September 29, 2009
Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemiasRobin E Norris, Peter C Adamson
Nature Reviews. Cancer|October 12, 2012
Challenges and opportunities in childhood cancer drug developmentRobin E Norris, Peter C Adamson
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
JAMA Pediatrics|August 14, 2013
Unintended consequences of regulatory initiatives in childhood cancer drug developmentPeter C Adamson
The Oncologist|January 17, 2020
Early Phase Pediatric Cancer Trials: Progress Highlights ChallengesPeter C Adamson
JAMA Pediatrics|June 3, 2014
Too few medicines for children with cancer--replyPeter C Adamson
Annals of Internal Medicine|July 6, 2022
My Patient PortalPeter C Adamson
Pediatric Radiology|December 17, 2008
Imaging in early phase childhood cancer trialsPeter C Adamson
Pediatric Blood & Cancer|April 5, 2021
Foreword to special issue on radiation oncologyPeter C Adamson, Giorgio Perilongo
Cancer Investigation|October 24, 2007
Tyrosine kinase inhibitors in pediatric malignanciesJeffrey M Skolnik, Peter C Adamson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
All dex'ed out with nowhere to go?Peter C Adamson, Jeffrey S Barrett
Cancer Chemotherapy and Pharmacology|September 29, 2009
Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemiasRobin E Norris, Peter C Adamson
Nature Reviews. Cancer|October 12, 2012
Challenges and opportunities in childhood cancer drug developmentRobin E Norris, Peter C Adamson
Pageof 18